

H A N D B O O K O F
Pharmaceutical
Manufacturing
Formulations

Uncompressed Solid Products

VOLUME 2

Sarfaraz K. Niazi



CRC PRESS

Boca Raton London New York Washington, D.C.

EXHIBIT

1033

12/6/19

024

Library of Congress Cataloging-in-Publication Data

Niazi, Sarfaraz, 1949–
Handbook of pharmaceutical manufacturing formulations / Sarfaraz K. Niazi.
p. cm.
Includes bibliographical references and index.
Contents: — v.2. Uncompressed solid products.
ISBN 0-8493-1751-7 (alk. paper)
1. Drugs — Dosage forms — Handbooks, manuals, etc. I. Title

RS200.N53 2004
615'19—dc21

2003051451

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher.

The consent of CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press LLC for such copying.

Direct all inquiries to CRC Press LLC, 2000 N.W. Corporate Blvd., Boca Raton, Florida 33431.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation, without intent to infringe.

Visit the CRC Press Web site at www.crcpress.com

© 2004 by CRC Press LLC

No claim to original U.S. Government works
International Standard Book Number 0-8493-1751-7
Library of Congress Card Number 2003051451
Printed in the United States of America 1 2 3 4 5 6 7 8 9 0
Printed on acid-free paper

Dedication

*Dedicated to the memory of
Takeru Higuchi*

Preface to the Series

No industry in the world is more highly regulated than the pharmaceutical industry because of potential threat to a patient's life from the use of pharmaceutical products. The cost of taking a new chemical entity (amortized over the cost of all molecules racing) to final regulatory approval is a staggering \$800 million, making the pharmaceutical industry one of the most research-intensive industries in the world. In the year 2004, it is anticipated that the industry will spend about \$20 billion on research and development. The generic market of drugs as the new entities come off patent is one of the fastest growing segments of the pharmaceutical industry, with every major multinational company having a significant presence in this field.

Whereas many stages of new drug development are inherently constrained with time, the formulation of drugs into desirable dosage forms remains an area where expediency can be practiced with appropriate knowledge by those who have mastered the skills of pharmaceutical formulations. The *Handbook of Pharmaceutical Manufacturing Formulations* is the first major attempt to consolidate the available knowledge about formulations in a comprehensive, and by nature a rather voluminous, presentation.

The book is divided into six volumes, based strictly on the type of formulation science involved in the development of these dosage forms: sterile products, compressed solids, uncompressed solids, liquid products, semisolid products, and OTC products. The separation of OTC products, even though they may easily fall into one of the other five categories, is made to comply with the industry norms of separate research divisions for OTC products. Sterile products require skills related to sterilization of product, and of less importance is the bioavailability issue, which is an inherent problem of compressed

dosage forms. These types of considerations have led to the classification of products into these six categories.

Each volume includes a description of regulatory filing techniques for the formulations described. Also included are the current regulatory guidelines on CGMP compliance specific to the dosage form. Advice is offered on how to scale up the production batches.

It is expected that formulation scientists will use this information to benchmark their internal development protocols and cut the race to file short by adopting formulae that have survived the test of time. Many of us who have worked in the pharmaceutical industry suffer from a close paradigm when it comes to selecting formulations — “not invented here” perhaps reigns in the mind of many seasoned formulations scientists subconsciously when they prefer to choose only a certain platform for development. It is expected that with the quick review of possibilities available to formulate made available in this book, scientists will benefit from the experience of others.

For the teachers of formulation sciences, this series offers a wealth of information. Whether it is a selection of a preservative system or the choice of a disintegrant, the series offers a wide choice to study and rationalize.

Many have assisted me in the development of this work that has taken years to compile, and I thank scores of my graduate students and colleagues for their help. A work of this size cannot be produced without errors, although I hope that these errors do not distract the reader from the utility of the book. I would sincerely appreciate if readers point out these mistakes for corrections in future editions.

Sarfaraz K. Niazi, Ph.D.
Deerfield, Illinois

Preface to the Volume

Uncompressed solid products formulations comprise aggregates of powders, such as powders for topical application, for use as insufflations, and for extemporaneous suspensions, as well as hard gelatin capsules or any other form wherein the final form is not compressed. The rationale for this clear demarcation of formulations based on their state of aggregation is important to understand. Whereas compressed solid products require formulation components to render them compressible while allowing free flow into compression cavities, such considerations are of lesser importance for uncompressed solid products. (The flow requirement nevertheless stays because the powders must be forced into capsule shells or poured into bottles or other packaging forms.) Uncompressed solid products on the other hand offer their own set of formulation problems related to segregation of powders due to static charges, environmental contamination during the filling process, and inevitable problems in wetting and dissolution, thus leading to possible bioavailability problems *in vivo*. In the series of steps that determine the ultimate dissolution of the product, however, uncompressed solid products are one critical step ahead of compressed solid products — disintegration. The formulator is advised to read Chapter 4 of this volume, which discusses guidelines on the waiver of bioavailability requirements. Substantial development costs can be reduced when a drug undergoes fast dissolution, and these considerations must therefore be part of any new formulation effort. The reader is also referred to Volume 1 of this series where current and proposed bioavailability guidelines are provided.

Chapter 1 addresses the fundamental issues of good manufacturing practices (GMPs). The chapter provides access addresses to all major guidelines around the world and also highlights the U.S. Food and Drug Administration (FDA) guidelines. A discussion of the most recent changes in the philosophy of establishing the GMP guidelines based on risk assessment is addressed in this chapter as well.

Chapter 2 presents a more recent discussion of how the U.S. FDA inspectors are supposed to conduct inspections; this topic is of continuous importance to all drug manufacturers. Although it is included in this volume, the guidelines apply to all dosage forms.

Chapter 3 discusses the topic of bioequivalence and bioavailability of solid products. Although this is discussed more thoroughly in Volume 1, the emphasis in Chapter 3 is placed on the guidelines to request a waiver

of bioavailability/bioequivalence testing; this is something of great importance to both the innovator and the generic drug manufacturer.

Chapter 4 highlights the manufacturing aspects of uncompressed drugs as well as various topics of general and specific interest.

Part II provides formulations for more than 400 pharmaceutical products. Included in part are not only the currently approved products, but also several innovative products such as small proteins, instantly liquefiable powders, and nanoparticles. Formulators are strongly urged to review the methodologies described here to serve as a reference point for their own formulations. Some combination products or dosage forms are described that are not currently approved by the FDA (i.e., not included in the *Orange Book*), and they may be in the development phase or in experimental phases. As is always the case, it is the responsibility of the manufacturer to ensure that the formulations used in the production do not violate any intellectual property or proprietary practice laws. The most effective means of establishing this is through a study of the *Orange Book*, which lists the exclusivities and unexpired patents. The patent numbers provided in the *Orange Book* should then be searched for collateral patents, the FDA Freedom of Information (FOI) database, and other literature to ensure that the intellectual or proprietary property rights are not violated.

Whereas coating solutions are not as important, as in the case of compressed solids, nevertheless, some capsules are coated and the granules that are filled in capsules for sustained or timed release are coated, utilizing nonpareil sugar beads most often. The coating solutions are described here, but the reader is further referred to Volume 1 for a detailed description of coating solutions that can be easily adapted to the product intended for formulation into a sustained release profile. Whereas some forms of powders are meant to be sterile, the sterility considerations are discussed in Volume 6.

The subject of powder technology is vast, with applications in many fields. The serious reader is referred to the journal *Advanced Powder Technology* (<http://www.vsppub.com/journals/jn-AdvPowTec.html>). Such advances as inhalation insulin in a powder form and the new science of nanoparticles opens a new phase of pharmaceutical research and development. Nanotechnology describes the ability to create new materials from building blocks the size of an atom cluster. Nanomaterials are powders and materials optimized at the nanoscale

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.